The American Diabetes Association and the European Association for the Study of Diabetes have published their first update since 2022 of their joint consensus on managing type 2 diabetes, and it advocates using GLP-1-based drugs or SGLT2 inhibitors earlier, potentially from diagnosis, to protect the heart and kidneys. The report appeared in Diabetologia on 2 … Read more
Orforglipron, Eli Lilly’s once-daily GLP-1 pill, did not raise the risk of heart attack, stroke or cardiovascular death compared with insulin glargine in 2,749 adults with type 2 diabetes and established heart or kidney disease, according to the ACHIEVE-4 trial published in The Lancet on 30 September. It is the first cardiovascular-outcomes trial of a … Read more
Survodutide, an experimental once-weekly injection from Boehringer Ingelheim that acts on both the GLP-1 and glucagon receptors, reduced body weight by 8.2% to 9.8% over 76 weeks in adults with obesity and type 2 diabetes, against 3.9% on placebo, in a phase 3 trial published in the New England Journal of Medicine on 1 October. … Read more
When a state Medicaid programme starts paying for GLP-1 drugs labeled for obesity, the bill for those drugs goes up. A study in JAMA Health Forum suggests the net increase is smaller than that figure implies, because some of the new obesity-labeled prescriptions appear to replace diabetes-labeled versions of the same molecules, which every state … Read more
A review of 34 randomised trials in PLoS Medicine has tested the standard first-line advice for polyendocrine metabolic ovarian syndrome (PMOS) — the condition long called polycystic ovary syndrome, or PCOS, recently renamed by an international consensus. Structured diet, exercise and behavioural programmes improved fasting insulin, and made regular menstrual cycles more likely, compared with … Read more
Two analyses of the SELECT trial, published a day apart, reach the same uncomfortable conclusion from different directions. The first, in the European Heart Journal, tried to work out how much of semaglutide’s 20% reduction in heart attacks, strokes and cardiovascular deaths runs through weight loss and the other risk factors it improves, and could … Read more
Adults with obesity and a raised inflammatory marker who were prescribed a GLP-1 receptor agonist had fewer deaths, heart attacks and strokes over the following decade than closely matched adults given an older weight or diabetes drug, according to a study published on 21 September in the American Journal of Cardiology. The gap was driven … Read more
Ultra-processed foods are associated with higher rates of seven major health outcomes, obesity and overweight among them, according to a dose-response meta-analysis of 51 prospective cohort studies covering 8,819,894 adults, published on 22 September 2026 in Family Medicine and Community Health. People in the highest intake groups had a 23% higher rate of obesity or … Read more